REPL: Bull Flag detected on 22 May 2026

REPL has formed a bull flag pattern following the FDA's second Complete Response Letter rejecting the BLA for RP1 in combination with nivolumab for advanced melanoma on April 10, 2026. The pattern shows perfect structure (score 15.0/15) with strong breakout potential (9.7/13) and solid volume confirmation (12.0/12), yielding an overall quality score of 82.7/98. Price sits at $5.22 between support at $4.69 and resistance at $5.54. The pattern reflects a 129.96% one-month recovery from lows near $2.09, suggesting short-covering and institutional repositioning. RSI at 59.12 indicates neither overbought nor oversold conditions, supporting continued upside potential.

In early May, shares surged more than 21% after a Wall Street Journal editorial criticized the FDA's rejection of RP1, and REPL saw aggressive buying interest around political and media pressure on the FDA, with price moving from the low $2.90s to above $4.25. As a pre-revenue biotech, the story centers on cash and burn; REPL reported $124.7M in cash at December 31, 2025, and $269.1M including short-term investments, with operating cash outflow of $66.0M for the quarter. Cantor Fitzgerald and Piper Sandler downgraded REPL from Overweight to Neutral, with Piper Sandler setting a $4 price target. The bull flag emerges amid regulatory and political uncertainty rather than fundamental improvement.

A successful breakout above $5.54 resistance would target a conservative measure move to $5.39, representing approximately 3% upside from the pattern's flagpole structure. Volume needs to sustain above the 6.97M twenty-day average (current flow at 4.56M represents 65% of normal), confirming institutional accumulation rather than retail speculation. The pattern invalidates decisively below $4.69 key support, where initial liquidation would accelerate toward $3.00-$3.50. With a 72.89% win probability, the setup suggests asymmetric risk-reward typical of biotech volatility patterns during narrative inflection points.

The FDA's Complete Response Letter cited insufficient efficacy data for RP1 plus nivolumab, establishing a regulatory ceiling despite short-term sentiment swings. Q3 FY25 showed zero product revenue and a steep operating loss of ~$71M, with free cash flow of -$66M per quarter, implying dilution or deep cost cuts ahead. The company noted that without timely accelerated approval, RP1 development is not viable and manufacturing operations will be curtailed. Volume ratio of 0.65 signals below-average conviction; sentiment remains fragile and vulnerable to negative news flow. The pattern rally depends entirely on FDA reversal or political intervention—clinical or regulatory setbacks will collapse support immediately to $2-$3 range.